Co-diagnostics, INC 10-Q quarterly reports

Co-Diagnostics reports a wider net loss for Q1 2026 due to increased R&D spending and lower other income, despite a rise in product revenue.

Co-Diagnostics reported a significant revenue decline and increased operating cash burn, leading to a 'going concern' warning despite recent capital raises.

Co-Diagnostics reports significant revenue decline and increased operating losses, raising substantial doubt about its ability to continue as a going concern while facing NASDAQ delisting risk.

Co-Diagnostics, Inc. reports a decrease in revenue for Q1 2025 compared to Q1 2024, while continuing to focus on the development and regulatory approval of its Co-Dx PCR platform.

Co-Diagnostics experienced a decrease in revenue for the third quarter of 2024, primarily due to a reduction in grant funding and product sales, while also seeing a net loss increase.

Co-Diagnostics saw a significant increase in revenue in the second quarter of 2024, primarily due to grant funding, while also experiencing a reduced net loss compared to the same period last year.

Co-Diagnostics experienced a decrease in revenue and a net loss in the first quarter of 2024, while also increasing investment in research and development.